Diseases

Roche wins approval of HPV test

April 25, 2011
J.K. Wall
Roche Diagnostics Corp. won regulatory approval for a new HPV test, giving it a technological edge in the $300 million market for automated cervical cancer tests.
More

FDA wants further testing of Lilly pancreas drug

April 16, 2011
Associated Press
Eli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed pancreas drug before it resubmits an application to have the drug approved for sale.
More

Firm joins race with IU autism drug

April 9, 2011
J.K. Wall
The Indiana University School of Medicine has licensed a pediatric psychiatrist's patent on an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed the patent to Indianapolis-based Confluence Pharmaceuticals Inc.
More

Regulators delay approval of Lilly's Alzheimer’s screen

March 18, 2011
Bloomberg News
The Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
More

Trade agency to probe Lilly's infringement claim

March 17, 2011
Bloomberg News
Eli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.
More

Lilly's Bydureon falls short of competitor in study

March 3, 2011
Bloomberg News
Bydureon, the diabetes drug being developed by Amylin Pharmaceuticals Inc., Eli Lilly and Co. and Alkermes Inc., didn’t control the disease better than Novo Nordisk A/S’s Victoza in a study.
More

Repeated price cuts take glow off Endocyte IPORestricted Content

February 12, 2011
Greg Andrews
New investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing reveals.
More

Diabetes boom sparks Roche expansion

February 12, 2011
J.K. Wall
Roche Diagnostics Corp. is expanding one of its Indianapolis manufacturing plants to keep up with growing sales of its leading brand of blood glucose monitors.
More

Head of Lilly's oncology unit resigning

January 25, 2011
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
More

Lilly imaging drug isn't ready for approval, FDA says

January 18, 2011
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer's disease isn't ready for approval, according to U.S. regulators.
More

Lilly's Solpura may lack data to prove effectiveness

January 10, 2011
Bloomberg News
Outside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency caused by cystic fibrosis, chronic pancreatitis or other conditions.
More

Roche acquires Marcadia Biotech

December 30, 2010
Chris O'Malley
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
More

Lilly suspends late-stage trial for melanoma drug

December 13, 2010
Bloomberg News
Eli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study died.
More

Q&A

December 8, 2010
J.K. Wall
Molecular biologist,David G. Skalnik will become associate dean for research and graduate education at the IUPUI School of Science in January. Since 1991, Skalnick has been a researcher at the Indiana University School of Medicine, leading a team of three in the study of epigenetics—factors that influence whether certain genes are turned on or turned off.
More

Study: Arthritis drug co-developed by Lilly shows promise

November 12, 2010
 IBJ Staff and Bloomberg News
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
More

Lilly makes $300M deal for Philadelphia drug company

November 8, 2010
J.K. Wall
Eli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients with Alzheimer's disease. The price could climb to $800 million if the agent is commercially successful.
More

UPDATE: Lilly, others see stock slide after drug rejection

October 20, 2010
Bloomberg News
Stock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
More

Lilly's Erbitux shows mixed results in cancer studies

October 11, 2010
Bloomberg News
In combination with chemotherapy, the drug failed to help colon-cancer patients in a European trial but did delay the spread of breast cancer in some patients with a certain type of aggressive tumor.
More

Diabetes research pioneer Kirtley dies at 96

August 25, 2010
Associated Press
Diabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a groundbreaking Eli Lilly researcher.
More

Lilly halts development of Alzheimer's drug

August 17, 2010
 IBJ Staff and Associated Press
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through 2014.
More

Positron has billion-dollar hopes for medical-imaging scanner

May 29, 2010
J.K. Wall
A maker of medical imaging equipment that recently moved its headquarters to Fishers has grand plans to reach $1 billion in sales and build a multimillion-dollar cyclotron facility in five years. But history shows Positron Corp. has been far better at losing money than making it.
More

Indianapolis startup attacks Alzheimer's diseaseRestricted Content

May 29, 2010
Norm Heikens
AgeneBio Inc. this month landed a $300,000 investment from the Indiana Seed Fund to fund operations, bolster its intellectual property, and begin learning how to make a drug into a once-a-day pill.
More

Lilly still waiting on once-weekly Byetta

May 12, 2010
J.K. Wall
The U.S. Food and Drug Administration last week pushed its self-declared deadline for rendering an approval decision on the drug Bydureon to Oct. 22. The previous deadline was in March.
More

New federal funds come with big goals

May 5, 2010
J.K. Wall
Indiana has now received nearly $50 million in federal bucks to digitize health care around the state. But the latest grant—$16 million to the Indiana Health Information Exchange—comes with specific, ambitious goals for health care providers.
More

Health care bill burns local tanning industry

March 26, 2010
Anthony Schoettle
With one of the nation's largest tanning-bed manufacturers and dozens of salons in central Indiana, a 10-percent tax on tanning could cost the region jobs.
More
Page  << 1 2 3 4 5 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am also a "vet" of several Cirque shows and this one left me flat. It didn't have the amount of acrobatic stunts as the others that I have seen. I am still glad that I went to it and look forward to the next one but I put Varekai as my least favorite.

  2. Looking at the two companies - in spite of their relative size to one another -- Ricker's image is (by all accounts) pretty solid and reputable. Their locations are clean, employees are friendly and the products they offer are reasonably priced. By contrast, BP locations are all over the place and their reputation is poor, especially when you consider this is the same "company" whose disastrous oil spill and their response was nothing short of irresponsible should tell you a lot. The fact you also have people who are experienced in franchising saying their system/strategy is flawed is a good indication that another "spill" has occurred and it's the AM-PM/Ricker's customers/company that are having to deal with it.

  3. Daniel Lilly - Glad to hear about your points and miles. Enjoy Wisconsin and Illinois. You don't care one whit about financial discipline, which is why you will blast the "GOP". Classic liberalism.

  4. Isn't the real reason the terrain? The planners under-estimated the undulating terrain, sink holes, karst features, etc. This portion of the route was flawed from the beginning.

  5. You thought no Indy was bad, how's no fans working out for you? THe IRl No direct competition and still no fans. Hey George Family, spend another billion dollars, that will fix it.

ADVERTISEMENT